Literature DB >> 6990171

Dopaminergic control of serum potassium.

M Bevilacqua, G Norbiato, U Raggi, P Micossi, E Baggio, M Prandelli.   

Abstract

Metoclopramide, a dopaminergic inhibitor, injected in 9 normal volunteers, was followed by a prompt decrease of serum potassium (10--20 min; p less than 0.01) and by an increase of plasma aldosterone (p less than 0.01). Renin slightly increased at 45 min (p less than 0.05); insulin and cortisol did not show any significant increase. The urinary excretion of potassium rose after metoclopramide (p less than 0.05). A bolus of aldosterone (250 micrograms i.v.) in 4 normal subjects was not followed by any modification of serum potassium, but increased urinary potassium excretion (p less than 0.05); the injection of metoclopramide in two patients with an aldosterone-secreting adenoma of the adrenal and in one patient with Addison's disease induced a decrease of serum potassium in absence of any modification of plasma aldosterone. The decrease of serum potassium after metoclopramide is not explained by changes of aldosterone or insulin, considered the most important hormonal controls of potassium. The rapidity of potassium decrease implies a change of distribution of potassium between extra- and intracellular compartments, which, in turn, may stimulate aldosterone secretion. It is conceivable that the dopaminergic system has a role in the control of serum potassium.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6990171     DOI: 10.1016/0026-0495(80)90002-5

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  7 in total

1.  Continuous multi-channel intravascular monitoring of the effects of dopamine and dobutamine on plasma potassium in dogs.

Authors:  H F Drake; M Smith; D R Corfield; T Treasure
Journal:  Intensive Care Med       Date:  1989       Impact factor: 17.440

2.  Effect of serotonin on plasma aldosterone in man.

Authors:  F Mantero; G Opocher; M Boscaro; D Armanini
Journal:  J Endocrinol Invest       Date:  1982 Mar-Apr       Impact factor: 4.256

3.  Metoclopramide, domperidone and dopamine in man: actions and interactions.

Authors:  T M MacDonald
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

4.  Stimulation of aldosterone secretion by metoclopramide is not affected by chronic converting enzyme inhibition.

Authors:  A G Dupont; P Vanderniepen; J J Smitz; R O Six
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

5.  Changes in electroretinogram and serum potassium during L-DOPA treatment in parkinsonism.

Authors:  D Terziivanov; M Filipova; I Janků; J Balík; V Filip; L Stika
Journal:  Arch Psychiatr Nervenkr (1970)       Date:  1983

6.  Atrial natriuretic factor inhibits metoclopramide stimulated aldosterone release in man.

Authors:  C C Lang; A R Rahman; A D Struthers
Journal:  Br J Clin Pharmacol       Date:  1991-07       Impact factor: 4.335

7.  Transient electroretinographic abnormalities that mimic those of KCNV2 retinopathy: a case report.

Authors:  Chihiro Kaizuka; Takaaki Hayashi; Kei Mizobuchi; Masaomi Kubota; Shinji Ueno; Tadashi Nakano
Journal:  Doc Ophthalmol       Date:  2021-03-18       Impact factor: 2.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.